BEAM Beam Therapeutics Inc.
FY2025 10-K
Beam Therapeutics Inc. (BEAM) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Fully integrated precision genetic medicines platform based on proprietary base editing gene editing technology without DNA double-strand breaks
- • New products/segments: Announced BEAM-304 for phenylketonuria (PKU) and advancing in vivo LNP liver-targeted base editors BEAM-302 (AATD) and BEAM-301 (GSDIa)
Management Discussion & Analysis
- • Revenue $139.7M in 2025 vs $63.5M in 2024 and $377.7M in 2023, primarily from license and collaboration agreements
- • Net loss $80.0M in 2025 vs $376.7M loss in 2024 and $132.5M loss in 2023, accumulated deficit $1.6B at 2025 year-end
Risk Factors
- • Cybersecurity risk oversight by Audit Committee with quarterly management updates and immediate alerts on significant incidents
- • Dependence on VP, IS with 25 years experience and CISSP and CISA certifications for cybersecurity program leadership
Financial SummaryXBRL
Revenue
$140M
Net Income
-$80M
Operating Margin
-274.6%
Net Margin
-57.2%
ROE
-6.5%
Total Assets
$1.5B
EPS (Diluted)
$-0.81
Operating Cash Flow
-$345M
Source: XBRL data from Beam Therapeutics Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Beam Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.